Abstract:
ABSTRACT
in the course of comparative practical characteristics, the clinical profile of two dosage forms benzatin benzylpenicillin at a dose of 2.4 million units and bicillin-5 was evaluated. The study included 60 people (33 women and 27 men aged 16-45 years) with confirmed chronic rheumatic heart disease (CRD) without signs of circulatory insufficiency. The evaluation of the effectiveness of benzylpenicillin was evaluated by EchoCG control and laboratory data indicating the activity of the process 6 and 12 months after regular intramuscular injection of one of the drugs once every 3 weeks. The administration of extenbenzatin at a dose of 2.4 million units (32 people) prevented the development of recurrent rheumatic fever, which was ensured by a likely stable concentration of benzatin benzylpenicillin for a 3-week period. With the injection of bicillin-5 1.5 million units (28 people), relapses of rheumocarditis were observed in 58% of cases, due to a decrease in the concentration of benzylpenicillin by 3 weeks. Thus, long-term preventive treatment with benzatin benzylpenicillin at a dose of 2.4 million units shows high effectiveness in preventing repeated attacks of rheumatic fever.
